Karyn T. O'neil BS, PhD

Karyn O’Neil is the CSO, Aro Biotherapeutics. She was previously the Venture Leader for Centyrex, a J&J Venture focused on designer protein platform technologies. She is co-inventor of the Centyrin patents, and has led the team focused on advancing the Centyrin platform since its inception.

Karyn’s team applied protein engineering, nucleic acid chemistry and chemical conjugation technologies to enable Centyrin – mediated intracellular delivery of nucleic acid cargos in a cell specific manner. Karyn joined Centocor/J&J in 2001 where, prior to working on Centyrins, she held positions of increasing responsibility, ultimately becoming a Director of Antibody Therapeutics. There she played a leadership role in the discovery & optimization of multiple clinical candidates.